Is Orion Oyj (HLSE:ORNBV) Fully Priced On Phase 3 Darolutamide Trial News?

What happened: Interim Phase 3 darolutamide data put Orion Oyj (HLSE:ORNBV) back in focus, alongside upgraded 2026 guidance and an upcoming executive team reshuffle. Key numbers: 1 day share price return 4.39%, 30 day 16.15%, year to date 52.21%, 3 year total shareholder return 182.48%, 5 year 203.26%. Why it matters: Bulls point to oncology progress and upgraded 2026 earnings guidance, while bears highlight the sharp rerating and analyst target gap, leaving the valuation debate centered on how dependable the oncology and branded medicines story is.

Interim Phase 3 darolutamide data put Orion Oyj (HLSE:ORNBV) back in focus, alongside upgraded 2026 guidance and an upcoming executive team reshuffle.

Bulls point to oncology progress and upgraded 2026 earnings guidance, while bears highlight the sharp rerating and analyst target gap, leaving the valuation debate centered on how dependable the oncology and branded medicines story is.